

John Mascarenhas, MD, reviews the patient selection of extended molecular panels and the appropriate interval for molecular profiling for the management of myelofibrosis. [[Targeted Oncology](#)]

Mount Sinai Health System developed the renal cell carcinoma asset for HiberCell, a Hell's Kitchen–based biotech firm that develops cancer therapies. [[Crain's Health Pulse](#)]

Ajai Chari, MD, discusses his patient and his research regarding T-Cell redirection therapy in multiple myeloma, [[Spectrum News: New York One - No Link Available](#)]

Matthew Galsky, MD, discusses the FDA approval of adjuvant nivolumab for high-risk urothelial carcinoma. [[Onclive](#)] [[Medscape](#)] [[Clinical Oncology News](#)]

Kenneth Davis, MD, and **Luis Isola, MD**, discuss how Mount Sinai Health System has received \$60 million from philanthropists James S. and Merryl H. Tisch to establish the Mount Sinai Tisch Cancer Center. [[Crain's Health Pulse](#)] [[Becker's Hospital Review](#)] [[Spectrum News: New York One - No Web Link Available](#)] [[GenomeWeb](#)] [[The Jewish Voice](#)]

Fred Hirsch, MD, PhD, comments on a study about adoptive cell therapy using tumor-infiltrating lymphocytes. [[Medscape](#)]

Ashley Tsang, MD, discusses how Mount Sinai Health System launched a comprehensive BRCA Program for men and women. [[Yonkers Times](#)]

Michael Crane, MD, discusses the rising number of cancer victims among Ground Zero responders and others who lived, worked or went to school near the World Trade Center, 20 years after 9/11. [[New York Post](#)]

Michael Crane, MD, reflects on the 20th anniversary of 9/11 and discusses Mount Sinai Health System's World Trade Center Health Program. [[WCBS News Radio](#)]

Ash Tewari, MD, discusses patient Tony Hillery's prostate cancer surgery and urging men to get screened. [[TODAY Online](#)]

Michael Zeidman, MD, discusses what stage 1A breast cancer means and how it is treated. [[SurvivorNet](#)]

Ash Tewari, MD, comments on the best way to recover urinary continence after prostatectomy at the American Urological Association Annual Meeting. [[MedPage Today](#)]

Stephanie Bernik, MD, comments on a study surrounding laws that notify women if they have dense breasts and those that mandate insurance coverage for additional testing are catching on and may help identify breast cancers earlier. [[HealthDay](#)]

Fred Hirsch, MD, PhD, discusses how the DESTINY-Lung01 study suggests that trastuzumab deruxtecan induces durable responses in HER2-mutated NSCLC. [[Healio: Hematology/Oncology](#)]

Stephanie Blank, MD, comments on the KEYNOTE-826 study and how the addition of pembrolizumab to chemotherapy significantly improved PFS and OS among women with cervical cancer. [[Healio: Hematology/Oncology](#)]

Charles Shapiro, MD, discusses how the BrighTNess trial establishes that carboplatin added to weekly paclitaxel increases the complete pathologic rate and EFS in triple negative breast cancer. [[Healio: Hematology/Oncology](#)] [[HealthDay](#)]

Charles Shapiro, MD, and Amy Tiersten, MD, comment on trials evaluating treatments for breast cancer presented at the European Society for Medical Oncology Congress 2021. [[Oncology](#)]

Ash Tewari, MD, discusses the special urgency of prostate cancer awareness month in the time of COVID-19. [[Our Town](#)]

Vinayak Wagaskar, MBBS, comments on a study presented at the European Society for Medical Oncology Congress 2021 on how adding abiraterone acetate to standard of care prolongs survival in prostate cancer subset. [[Healio: Hematology/Oncology](#)]

Charles Shapiro, MD, comments on a study presented at the European Society for Medical Oncology Congress 2021 regarding how patients with pretreated locally advanced or metastatic HER2-positive breast cancer had significantly longer PFS after treatment with [vic-]trastuzumab duocarmazine vs. physician's choice of treatment. [[Healio: Hematology/Oncology](#)]

Amy Tiersten, MD, comments on a study presented at the European Society for Medical Oncology Congress 2021 on how adding pembrolizumab to chemotherapy extends OS in triple-negative breast cancer subset. [[Healio: Hematology/Oncology](#)]

Adriana Pedraza, MD, comments on a study presented at the European Society for Medical Oncology Congress 2021 on the STAMPEDE trial and how abiraterone acetate plus prednisolone is the new standard of care in prostate cancer subset. [[Healio: Hematology/Oncology](#)]